Bicara Therapeutics Inc. Common Stock (BCAX) Earnings
Bicara Therapeutics Inc. Common Stock is expected to report next earnings on August 11, 2026 (in NaN days), with a consensus EPS estimate of $-0.78. BCAX has beaten EPS estimates in 2 of its last 4 reported quarters (average surprise -5.6% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 11, 2026 | $-0.64 | $-0.93 | -45.3% | — | — |
| Mar 30, 2026 | $-0.66 | $-0.39 | +41.3% | — | — |
| Aug 12, 2025 | $-0.54 | $-0.50 | +7.4% | — | — |
| Mar 27, 2025 | $-0.31 | $-0.39 | -25.8% | — | — |
| Sep 13, 2024 | — | $-0.27 | — | — | — |
| Jun 30, 2024 | — | $-0.27 | — | — | — |
| Dec 31, 2023 | — | $-0.23 | — | — | — |
| Sep 30, 2023 | — | $-0.42 | — | — | — |
| Jun 30, 2023 | — | $-0.15 | — | — | — |
| Mar 31, 2023 | — | $-0.15 | — | — | — |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q1 FY2026 · May 11, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
### Leadership and Organizational Updates - Former CMO Dave Rabin transitioned to a senior executive advisor role; Bill Shellman, former executive vice president of clinical development, stepped into the CMO position. - Chris Sarkey joined as chief commercial officer to build out commercial, market access, and operational teams in preparation for potential launch, supporting the company's transition from clinical-stage to commercial-stage. ### Lead Program (Fisera) Clinical Progress - Fisera is a bifunctional EGFR-directed antibody with a TGF-beta ligand trap, developed for frontline recurrent/metastatic HPV-negative head and neck cancer. The company remains on track to reach substantial enrollment in the pivotal Fortify HN01 trial by the end of 2026, positioning for an interim analysis in mid-2027 to support potential accelerated approval. - A peer-reviewed manuscript of Phase 1b expansion cohort data for Fisera 1500mg weekly plus pembrolizumab was published in the *Journal of Clinical Oncology*, validating the candidate's differentiated mechanism and clinical benefits. - Based on FDA discussions, the company plans to initiate a third-quarter 2026 alternative dosing study evaluating a 12-week loading phase of 1500mg weekly Fisera plus pembrolizumab, followed by randomization to either continued weekly dosing or 2250mg every three-week maintenance; the study will enroll 150-200 patients with progression-free survival as the primary endpoint. - Updated long-term follow-up data across all three Phase 1b Fisera dose cohorts will be presented at ASCO 2026, including three-year follow-up for the 1500mg weekly pivotal dose cohort, with additional data on TGF-beta inhibition mechanism. ### Pipeline Expansion - Two investigator-sponsored studies of Fisera in locally advanced head and neck cancer are initiated, and additional expansion cohorts are enrolling to inform broader indication expansion: frontline recurrent/metastatic HPV-negative head and neck cancer with CPS ≤1, frontline recurrent/metastatic HPV-positive head and neck cancer in heavy smokers. - Beyond head and neck cancer, Fisera is being evaluated in a Phase 1b expansion cohort for third-line plus metastatic colorectal cancer, with proof of concept already observed in cutaneous squamous cell carcinoma and anal canal cancer. The company is taking a measured approach to further investment, requiring a high bar of differentiated clinical value to advance new indications.
Guidance
• The company maintains guidance that the interim analysis for potential accelerated approval of Fisera in the Fortify HN01 trial will occur in mid-2027. • Full-year 2026 operating expenses are expected to increase, reflecting higher investment in the Fortify HN01 trial, the new alternative dosing study, and pre-commercial infrastructure buildout. • The current cash position, after the February 2026 public offering, provides sufficient runway into the first half of 2029 to support planned clinical and pre-commercial activities. • No changes to previously stated development timelines for expanded indication cohorts; data timing for non-pivotal expansion cohorts will be shared in future updates.
Segment performance
Bicara Therapeutics is a clinical-stage biotech company with a single lead product candidate, Phytherafisp-alpha (Fisera, referred to as Phycera/Pfizer in the transcript). As the company is still in clinical development and not yet commercial, no product segment revenue is reported. Total operating expenses for Q1 2026 increased year-over-year from Q1 2025, driven by higher clinical operations, development (including manufacturing for the pivotal Fortify HN01 trial), and personnel-related costs. The company ended Q1 2026 with $539.8 million in cash, cash equivalents, and marketable securities, following an oversubscribed public offering in February 2026 that generated $161.8 million in net proceeds.
Risks & headwinds
• Forward-looking statements, including clinical trial outcome and launch timing projections, are subject to inherent risks that could cause actual results to differ materially, as detailed in the company's recent SEC filings. • Clinical development of Fisera carries inherent uncertainty: trial enrollment could be delayed, interim efficacy and safety data may not support approval or further development, and competitive developments could alter the commercial landscape. • The alternative dosing study is not powered for formal non-inferiority analysis, so it may not generate data sufficient to support inclusion of the maintenance regimen in the initial label. • While the company expects event rates for overall survival analysis to be faster than competitors due to the focus on high-unmet-need HPV-negative patients, there is no guarantee this timeline will hold as anticipated.
Analyst Q&A
Q: What benchmarks can we expect for the three-year ASCO overall survival data in HPV-negative head and neck, and will we see correlations between TGF-beta inhibition (PD) and response rates?
A: One ASCO abstract will cover three-year median follow-up for the 1500mg cohort, where prior data shows Pembrolizumab delivers 15-20% three-year overall survival in the HPV-negative subset, and the data will clarify the immunotherapy survival tail driven by TGF-beta inhibition. A second abstract will confirm that TGF-beta inhibition drives deeper, more durable responses than competing agents, leading to superior overall survival benefit.
Q: A competitor upsized their frontline HPV-negative trial enrollment by 200 patients—does this impact Fortify HN01's size, and how has the competitive timing gap changed?
A: The competitor's trial upsize reflects an imbalance in HPV-negative patient enrollment in their study, with no read-through to the design or size of Bicara's Fortify HN01 trial. Bicara's strong execution of Fortify HN01 has narrowed perceived timing gaps, and the company still believes it has strong potential to deliver the first-in-class Fisera approval.
Q: What is the commercial and competitive value of the 12-week loading/every three-week maintenance dosing regimen beyond FDA Project Optimus requirements?
A: Project Optimus requirements have already been satisfied for the 1500mg weekly dose in the pivotal trial; this alternative regimen is a separate, parallel study. Efficacy remains the primary driver of commercial differentiation, and the initial 12-week weekly loading maximizes rapid, deep durable responses. Adding a convenient every three-week maintenance regimen optimizes the product profile across efficacy, tolerability, and patient/provider convenience, supporting competitive differentiation.
Q: What is the high bar for advancing Fisera in metastatic colorectal cancer and other expansion cohorts, and when can we expect data from these cohorts?
A: Expansion cohorts for CPS <1 head and neck and heavy-smoking HPV-positive head and neck are exploring biologically supported, high unmet need populations that represent meaningful market segments, following early promising responses in dose-escalation data. For CRC and all new indications, the high bar is clear evidence that Fisera can deliver differentiated clinical value relative to existing and emerging competitive options, given the company has multiple high-priority opportunities for capital allocation. No specific timing for non-pivotal cohort data has been set, and updates will be provided in future disclosures.